top of page


Potential breakthrough therapy for uterine fibroids and endometriosis. 


Hugging a Pillow

Protected by three US patents (10,251,836, 11,116,718, and 12,005,138). Clinical efficacy testing starts with Phase IIb.

Optimal use of the most promising drug: ultra-low doses of a specific Selective Progesterone Receptor Modulator (SPRM) are delivered by a novel route, directly to affected tissues:


Greater Efficacy: High local drug concentrations result in strong therapeutic action at a small fraction of oral dose – superior to other therapies.


Limited Side Effects: Unlike other hormonal therapies (e.g., Lupron Depot®), Premring will NOT be associated with severe menopausal symptoms, such as hot flashes and bone loss.


Safe Long-Term Therapy: Improved safety permits long-term treatment (not an option for other hormonal medications), greatly reducing the need for hospitalizations and radical surgeries.

bottom of page